Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | FRK | P42685 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.40 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.40 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.40 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.40 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.40 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6492211 | 0.80 | MAPK14 (0.66) | MAPK14 | |
| SCHEMBL6490407 | 0.80 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL6480518 | 0.77 | MAPK14 (0.68) | MAPK14 | |
| SCHEMBL6486365 | 0.77 | MAPK14 (0.68) | MAPK14 | |
| SCHEMBL6491709 | 0.76 | MAPK14 (0.63) | MAPK14GAA | |
| SCHEMBL6486370 | 0.75 | MAPK14 (0.72) | MAPK14 | |
| SCHEMBL6479939 | 0.75 | MAPK14 (0.68) | MAPK14 | |
| SCHEMBL6479610 | 0.74 | MAPK14 (0.67) | MAPK14 | |
| SCHEMBL6479938 | 0.73 | MAPK14 (0.66) | MAPK14 | |
| SCHEMBL6613565 | 0.73 | MAPK14 (0.65) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790846-B2 | SUCH AS 2-ETHYOXYMETHYL-4-(4-FLOUROPHENYL)-3-PYRIDIN-4-YL-2H-ISOXAZOL-5-ONE FOR INHIBITION OF THE RELEASE OF INFLAMMATORY CYTOKINES SUCH AS INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR; TREATMENT OF ARTHRITIS AND CONGESTIVE HEART FAILURE | THE PROCTER & GAMBLE COMPANY | 2004-09-14 | — | — | US | claimed |
| EP-1392299-A1 | ISOXAZOLONE COMPOUNDS USEFUL IN TREATING DISEASES ASSOCIATED WITH UNWANTED CYTOKINE ACTIVITY | THE PROCTER & GAMBLE COMPANY (US) | 2004-03-03 | — | — | EP | claimed |
| US-20030096814-A1 | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | PROCTER & GAMBLE COMPANY, THE | 2003-05-22 | — | — | US | claimed |
| WO-2002094266-A1 | ISOXAZOLONE COMPOUNDS USEFUL IN TREATING DISEASES ASSOCIATED WITH UNWANTED CYTOKINE ACTIVITY | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-28 | — | — | WO | claimed |
| US-6919346-B2 | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | THE PROCTER & GAMBLE COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-6790846-B2 | SUCH AS 2-ETHYOXYMETHYL-4-(4-FLOUROPHENYL)-3-PYRIDIN-4-YL-2H-ISOXAZOL-5-ONE FOR INHIBITION OF THE RELEASE OF INFLAMMATORY CYTOKINES SUCH AS INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR; TREATMENT OF ARTHRITIS AND CONGESTIVE HEART FAILURE | THE PROCTER & GAMBLE COMPANY | 2004-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096814-A1 | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | TNF, IL5, GPR35 | MAPK14 1280/4885GAA 522/4885PRKD3 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.